Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 24

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 24
---
 which consists of 622,600
shares of Alzheon’s preferred stock, may create synergies for the post-merger combined company to potentially provide a diagnostic
tool consisting of APOE genotype and miRNA panel testing for their therapeutic offering. Further, DiamiR’s technology and biomarker
panels can facilitate identification of new indications for repurposed drugs, such as SACT-1 in our pipeline, an agent with previously
unrecognized kinase inhibitory activity against MEK5/ERK5 signaling pathway that has shown promise in neuroblastoma.

As described below,
while building Aptorum’s pipeline via acquisitions and internal efforts, the Company’s executives have accumulated
expertise in clinical studies and services. We recognize the importance of effective biomarkers for drug development, and therefore,
deem DiamiR’s programs as highly synergistic with ours. As a post-merger combined company, the Company plans to utilize
DiamiR’s biomarker panels in various clinical studies, including through collaborations with academic institutions and
clinical centers in the US and other countries through Company CEO’s extensive global medical network,
expanding therapeutic focus and geographical outreach for the combined company.

In approving the Letter of Intent and the Merger, Company’s board
of directors considered the pros and cons of the DiamiR Merger versus other alternatives, which is likely a delisting of Company’s
Class A Ordinary Shares from Nasdaq if the Merger is not completed, and the opportunities and risks presented with the DiamiR Merger.

<div align='center'>6</div>

In particular, Company’s board of directors took into account the following reasons, facts and circumstances in approving the DiamiR Merger:

| ● | the potential for DiamiR’s product candidates in brain health,                         
 cancer and inflammatory diseases to create long term value for Company’s stockholders; |

| ● | the potential synergies available when combining Company’s existing                                      
 SACT-1 therapeutic program for neuroblastoma and potentially other indications with DiamiR’s technology; |

| ● | the ability of the business combination to facilitate re-commencing                                                                      
 of clinic services by the Company including in the growing market of minimally invasive diagnostic solutions for clinical trial support; |

| ● | the potential enhanced ability to raise capital utilizing 
 a broader potential product portfolio;                    |

| ● | Company’s projected cash position and the difficulties the Company    
 has encountered in raising sufficient capital on a stand-alone basis; |

| ● | the risks of continuing